| Racial and ethnic disparities in hematologic malignancies K Kirtane, SJ Lee Blood, The Journal of the American Society of Hematology 130 (15), 1699-1705, 2017 | 134 | 2017 |
| Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead K Kirtane, H Elmariah, CH Chung, D Abate-Daga Journal for immunotherapy of cancer 9 (7), 2021 | 124 | 2021 |
| Recent advances and future directions in clinical management of head and neck squamous cell carcinoma J Muzaffar, S Bari, K Kirtane, CH Chung Cancers 13 (2), 338, 2021 | 96 | 2021 |
| Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal A Li, Q Wu, C Davis, KS Kirtane, PD Pham, ML Sorror, SJ Lee, AK Gopal, ... Biology of Blood and Marrow Transplantation 25 (3), 570-576, 2019 | 55 | 2019 |
| Patient-reported outcomes in acute myeloid leukemia: Where are we now? SA Buckley, K Kirtane, RB Walter, SJ Lee, GH Lyman Blood Reviews 32 (1), 81-87, 2018 | 46 | 2018 |
| Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma CH Chung, J Li, CE Steuer, P Bhateja, M Johnson, J Masannat, MI Poole, ... Clinical Cancer Research 28 (11), 2329-2338, 2022 | 35 | 2022 |
| Intensity of end-of-life care for patients with hematologic malignancies and the role of race/ethnicity K Kirtane, L Downey, SJ Lee, JR Curtis, RA Engelberg Journal of palliative medicine 21 (10), 1466-1471, 2018 | 31 | 2018 |
| Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of phase I … CH Chung, M Bonomi, CE Steuer, J Li, P Bhateja, M Johnson, J Masannat, ... Cancers 13 (5), 1180, 2021 | 30 | 2021 |
| Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline E Yilmaz, N Ismaila, JE Bauman, R Dabney, G Gan, R Jordan, M Kaufman, ... Journal of Clinical Oncology 41 (5), 1132-1146, 2023 | 24 | 2023 |
| T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma X Wang, J Muzaffar, K Kirtane, F Song, M Johnson, MJ Schell, J Li, ... Journal for immunotherapy of cancer 10 (6), 2022 | 15 | 2022 |
| Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial NF Saba, CE Steuer, A Ekpenyong, A McCook-Veal, K Magliocca, M Patel, ... Nature medicine 29 (4), 880-887, 2023 | 14 | 2023 |
| Change in patients’ perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma A Barata, AI Hoogland, A Kommalapati, J Logue, T Welniak, KA Hyland, ... Transplantation and cellular therapy 28 (7), 401. e1-401. e7, 2022 | 14 | 2022 |
| “I have cancer during COVID; that’sa special category”: A qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic K Kirtane, C Geiss, B Arredondo, AI Hoogland, CH Chung, J Muzaffar, ... Supportive Care in Cancer 30 (5), 4337-4344, 2022 | 14 | 2022 |
| TCR gene-engineered cell therapy for solid tumors E Tan, N Gakhar, K Kirtane Best Practice & Research Clinical Haematology 34 (3), 101285, 2021 | 14 | 2021 |
| Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study. CH Chung, MR Bonomi, CE Steuer, MJ Schell, J Li, M Johnson, ... Journal of Clinical Oncology 38 (15_suppl), 6515-6515, 2020 | 14 | 2020 |
| Leaving footprints, not scars: A qualitative pilot study of Hispanic mothers’ willingness to communicate with dependent children about an advanced cancer diagnosis ET Loggers, K Kirtane, R Palacios, F Lewis Supportive Care in Cancer 27, 1573-1578, 2019 | 12 | 2019 |
| Duration of Targeted Therapy in Patients with Advanced Non–Small-Cell Lung Cancer Identified by Circulating Tumor DNA Analysis KL Reckamp, T Patil, K Kirtane, TA Rich, CR Espenschied, CM Weipert, ... Clinical lung cancer 21 (6), 545-552. e1, 2020 | 11 | 2020 |
| Emerging therapies for radioactive iodine refractory thyroid cancer K Kirtane, MY Roth Current Treatment Options in Oncology 21 (3), 18, 2020 | 11 | 2020 |
| A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). NF Saba, A Ekpenyong, A McCook-Veal, M Patel, NC Schmitt, WA Stokes, ... Journal of Clinical Oncology 40 (16_suppl), 6008-6008, 2022 | 9 | 2022 |
| Longitudinal collection of patient-reported outcomes and activity data during CAR-T therapy: feasibility, acceptability, and data visualization LB Oswald, X Li, R Carvajal, AI Hoogland, LM Gudenkauf, DK Hansen, ... Cancers 14 (11), 2742, 2022 | 9 | 2022 |
